Breakthrough trial tests Triple-Threat drug cocktail against aggressive lung cancer
NCT ID NCT07245446
Summary
This study is testing whether adding one of two experimental drugs to a new immunotherapy (ivonescimab) and standard chemotherapy works better for people newly diagnosed with extensive-stage small cell lung cancer. Researchers want to see which combination shrinks tumors most effectively while being safe. About 180 adults will be randomly assigned to receive one of three different drug combinations and monitored for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanghai Pulmonary Hospital Affiliated to Tongji University
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi'an, Shaanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.